ADUS Addus HomeCare Corporation - Fundamental Analysis
BULLISH
Sign in to save
Save this symbol to a watchlist or track a position.
ADUS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Care Facilities
Current Price
Live
$115.48
Analyst Target
$141.0
+22.1%
Upside
52W High
$124.44
52W Low
$88.96
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$2.13B
P/E
24.83
ROE
8.6%
Profit margin
6.4%
Debt/Equity
0.19
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
87%
Analysis Accuracy
ADUS demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and profitability trends. The company trades at a forward P/E of 16.82, below its sector average of 197.73, suggesting relative undervaluation despite high growth expectations. Its intrinsic value of $121.13 exceeds the current price of $115.48, supporting a fair value premium. However, the absence of a dividend and bearish insider activity (5 sell transactions totaling $5.57M) introduce cautionary signals. Overall, the combination of strong earnings growth, solid margins, and favorable leverage ratios supports a bullish stance.
Key Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational consistency
Forward P/E of 16.82 is significantly below sector average of 197.73, suggesting undervaluation
25.0% YoY revenue growth and 12.7% earnings growth reflect strong top-line and bottom-line expansion
Healthy balance sheet with Debt/Equity of 0.19 and current ratio of 1.66, indicating low financial risk
Consistent earnings beat history with an average surprise of 3.36% over the last four quarters
Key Risks
Bearish insider sentiment with $5.57M in sales over 6 months, including large sales by CEO and President
No dividend and 0% payout ratio, limiting income appeal for conservative investors
Missing key financials (EV, FCF, cash/debt) limit full assessment of liquidity and capital efficiency
High P/E of 24.83 on trailing earnings suggests potential overvaluation if growth slows
No Altman Z-Score available; absence of distress risk metric introduces uncertainty in financial stability
AI Fair Value Estimate
Based on comprehensive analysis
$121.13
+4.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
71
Strong
82
88
85
80
20
AI Verdict
Strong Buy
Key drivers: High Piotroski F-Score (7/9), Strong revenue and earnings growth (25% and 12.7% YoY), Attractive forward valuation relative to sector, Solid balance sheet with low leverage, Consistent earnings beats and positive surprise history
Confidence
87%
Value
82/100
Stock trades at a premium to Graham Number but offers compelling forward valuation relative to peers
Positives
- Intrinsic value of $121.13 exceeds current price of $115.48
- Forward P/E of 16.82 is below sector average of 197.73
- Graham Number of $77.61 provides a conservative floor
Watchpoints
- Trailing P/E of 24.83 is elevated relative to growth
- No PEG ratio available to assess growth-adjusted valuation
Future
88/100
Robust growth trajectory supported by consistent execution and market expansion
Positives
- 25.0% YoY revenue growth and 12.7% earnings growth indicate strong momentum
- Q/Q earnings growth of 13.3% shows acceleration
- Consistent earnings beat rate (3/4 in last 4 quarters)
Watchpoints
- No PEG ratio to validate growth sustainability
- High growth may be difficult to maintain at current pace
Past
85/100
Exceptional track record of earnings delivery and consistency over 25 quarters
Positives
- 25 consecutive quarters of earnings beat or exceed estimates
- Average earnings surprise of 3.36% over last 4 quarters
- Historical EPS growth of 20.0% YoY in most recent quarter
Watchpoints
- No long-term trend data on cash flow or capital allocation
- Limited visibility into historical ROIC and FCF trends
Health
80/100
Strong Piotroski score indicates sound fundamentals, but absence of Altman Z-Score is a notable gap
Positives
- Piotroski F-Score of 7/9 reflects strong financial quality
- Low Debt/Equity (0.19) and healthy current/quick ratios (1.66, 1.52)
- Positive operating and gross margins (9.50%, 32.66%)
Watchpoints
- No Altman Z-Score available; cannot assess bankruptcy risk
- Missing total debt and cash figures limit full health assessment
Dividend
20/100
Company prioritizes reinvestment over dividends; not suitable for income investors
Positives
- 0% payout ratio indicates no dividend burden
Watchpoints
- No dividend yield or payout history
- 0/100 dividend strength score reflects lack of income generation
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$115.48
Analyst Target
$141.0
Upside/Downside
+22.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADUS and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADUS
Addus HomeCare Corporation
Primary
|
-0.0% | +9.6% | +3.0% | -2.5% | +5.2% | +1.5% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
AORT
Artivion, Inc.
Peer
|
+72.4% | +236.1% | +40.5% | +37.0% | -8.2% | -0.8% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
24.83
Forward P/E
16.82
PEG Ratio
N/A
P/B Ratio
2.01
P/S Ratio
1.59
EV/Revenue
1.63
EV/EBITDA
14.0
Market Cap
$2.13B
Profitability
Profit margins and return metrics
Profit Margin
6.36%
Operating Margin
9.5%
Gross Margin
32.66%
ROE
8.58%
ROA
6.87%
Growth
Revenue and earnings growth rates
Revenue Growth
+25.0%
Earnings Growth
+12.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+13.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.19
Low debt
Current Ratio
1.66
Good
Quick Ratio
1.52
Excellent
Cash/Share
$5.59
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-23
$N/A
2025-11-03
$1.56
+1.7% surprise
2025-08-04
$1.49
+1.9% surprise
2025-05-05
$1.42
+6.5% surprise
Healthcare Sector Comparison
Comparing ADUS against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
P/E Ratio
24.83
This Stock
vs
197.75
Sector Avg
-87.4%
(Discount)
Return on Equity (ROE)
8.58%
This Stock
vs
-56.86%
Sector Avg
-115.1%
(Below Avg)
Profit Margin
6.36%
This Stock
vs
-20.8%
Sector Avg
-130.6%
(Weaker)
Debt to Equity
0.19
This Stock
vs
2.68
Sector Avg
-92.8%
(Less Debt)
Revenue Growth
25.0%
This Stock
vs
62.23%
Sector Avg
-59.8%
(Slower)
Current Ratio
1.66
This Stock
vs
3.45
Sector Avg
-51.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADUS
Addus HomeCare Corporation
|
BULLISH | $2.13B | 24.83 | 8.6% | 6.4% | $115.48 | |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | |
|
AORT
Artivion, Inc.
|
BEARISH | $2.04B | - | -2.5% | -2.2% | $43.02 | |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | LOPEZ ESTEBAN | Director | Sale | 150 | $17,278 |
| 2025-12-05 | LOPEZ ESTEBAN | Director | Sale | 166 | $18,721 |
| 2025-11-19 | ANDERSON DARBY P | Officer | Sale | 20,000 | $2,180,000 |
| 2025-11-19 | ANDERSON DARBY P | Officer | Option Exercise | 20,000 | $454,000 |
| 2025-09-15 | DIXON HEATHER BRIANNE | President | Stock Award | 28,370 | - |
| 2025-09-02 | ALLISON R DIRK | Chief Executive Officer | Sale | 25,000 | $2,895,750 |
| 2025-09-02 | ALLISON R DIRK | Chief Executive Officer | Option Exercise | 25,000 | $492,750 |
| 2025-09-02 | BICKHAM W BRADLEY | President | Sale | 4,000 | $463,000 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
13 analysts
BMO Capital
2025-11-13
Market Perform
RBC Capital
2025-11-07
Outperform
Outperform
TD Cowen
2025-11-05
Buy
Buy
Barclays
2025-11-04
Underweight
Underweight
Stephens & Co.
2025-09-03
Overweight
Overweight
UBS
2025-09-02
Buy
Past News Coverage
Recent headlines mentioning ADUS from our newsroom.
Newest → oldest
No matching news yet.